Starting off day 2 strong at the #AUAARC with the famous Howard Goldman, MD (his 25th year at the course)! So fortunate to be rounding out our training with the best by learning from the best! @CleClinicUro @CleClinicUroRes @JasonScovell @GrossMedicine @RossLiao @drjkaouk

This is shocking 😮. Just happened at the start of #ADA2026 Scientific Sessions.

It's entirely plausible that renaming Grade Group 1 (Gleason 6) PrCa can save a whole lot of lives. Consider reading and discussing. Editorial by @OtisBrawley @dr_coops @VickersBiostats @GladellPaner @UCLAHealth @UCLAHealthJCCC jamanetwork.com/journals/jam…

🚨 PROTEUS: perioperative apalutamide moves into high-risk localized #prostatecancer Just out in @NEJM 🧬 2109 men w/ high-risk localized or locally advanced PCa randomized to ADT apalutamide vs ADT placebo around radical prostatectomy. 🎯 Both stated primary endpoints met. ⚠️ But the trial deserves nuance. Thread 🧵 #ASCO26 @ASCO @PCF_Science

RAS finally getting drugged is one of the great stories in modern biology, and almost nobody outside oncology understands why it's such a big deal. YOU'LL LEARN SOMETHING AWESOME TODAY. i am going to keep this as understandable (and simple) as i can. OPEN THE THREAD. 🧵

Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived #ASCO26

RT @LauraBukavinaMD: En bloc cystectomy is proving to be a powerful approach in challenging cx> post-EV/P, bulky fibrotic disease and EV/P…

The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery. This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives). It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense. ‘It is the first companion diagnostic approval in the field of blood-based MRD.’ natera.com/company/news/sign…

Timely evaluation of hematuria remains a major failure point in bladder cancer diagnosis and it’s getting worse. @UrolOncol @UroDocAsh @KKBree @ValGraj @daniel_igel @ar_steinmetz authors.elsevier.com/a/1mFJo…

The word on the street is true — I am a #bluelightbeliever 😂

We recently got a brand spanking🔎🔎 new @PhotocureASA Blue 💙 light system @CleClinicUro and I am slowly convincing 1 resident at a time the incredible value in #bladdercancer starting w/ @eiftu

Force of nature #hadleywood giving the #WomenofGURS lecture at @SocietyGURS Congress, sharing her experiences and incredible insights. Lucky to call her a colleague, mentor and friend 🤍 @mdewittfoy

Can you tell us how he died, where, and why?

👏 Big congrats to @uroegg! New chair of urology at @UclaUrology

It is harder than ever to believe in our democracy. It has been attacked by billionaires and hollowed out by its failure to respond to working peoples’ struggles. But on this campaign, we dreamed of a new day. And we have won it together.

Congratulations to our fabulous chiefs @JasonScovell @eiftu on their #SUOMatch @CleClinicUro

Our stellar @CleClinicUro resident @eiftu Haile presenting our work on performance of isoPSA in Black and non-white men Interestingly, it seems to perform better! Keep an eye out for her!! #AUA2025 @rabouassalymd @cjweight @TunaBeksac @hjwang26 @samhaywoodmd @JasonScovell

Honored to be able to hear Dr. Jennifer Miles-Thomas, treasurer-elect of @AmerUrological, speak at the @SWIUorg meeting at the AUA. Glass ceiling SHATTERED! #Firsts #NotLasts #AUA25